Preferred Label : ponatinib hydrochloride;
UMLS semantic type : T109 - Organic Chemical; T121 - Pharmacologic Substance;
CAS number : 96R6PU3D8J;
UNII : 96R6PU3D8J;
InChIKey : BWTNNZPNKQIADY-UHFFFAOYSA-N;
Origin ID : M0588224;
UMLS CUI : C2981174;
CISMeF manual mappings
- Exact mapping(s) to DCI
- Related record
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/portail/jcms/c_2780980/fr/iclusig
2017
false
false
false
France
French
evaluation of the transparency committee
administration, oral
ponatinib hydrochloride
ponatinib
ponatinib
imidazoles
pyridazines
---
http://www.has-sante.fr/portail/jcms/c_2623462/fr/iclusig
2016
false
true
false
France
French
evaluation of the transparency committee
ponatinib hydrochloride
ponatinib
administration, oral
treatment outcome
antineoplastic agents
leukemia, myeloid, accelerated phase
blast crisis
leukemia, myeloid, chronic-phase
leukemia, lymphocytic, acute, L2
protein kinase inhibitors
orphan drug production
insurance, health, reimbursement
protein-tyrosine kinases
Tyrosine Kinase Inhibitors
precursor cell lymphoblastic Leukemia-Lymphoma
ponatinib
imidazoles
pyridazines
---
BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib),
BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk
of Hepatitis B Reactivation
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58222a-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
fusion proteins, bcr-abl
protein kinase inhibitors
Imatinib Mesylate
risk
hepatitis b virus
imatinib
nilotinib
nilotinib
bosutinib
bosutinib
Dasatinib
dasatinib
ponatinib hydrochloride
ponatinib
Tyrosine Kinase Inhibitor
Hepatitis B reactivation
guidelines for drug use
continuity of patient care
mass screening
hepatitis B
hepatitis B
Tyrosine Kinase Inhibitors
nilotinib
ponatinib
pyrimidines
imidazoles
pyridazines
aniline compounds
nitriles
quinolines
---
http://www.has-sante.fr/portail/jcms/c_2012843/fr/iclusig
http://www.has-sante.fr/portail/jcms/c_2012843/fr/iclusig-ponatinib-inhibiteur-de-tyrosine-kinase
2015
false
true
false
France
French
evaluation of the transparency committee
ponatinib hydrochloride
ponatinib
administration, oral
treatment outcome
antineoplastic agents
leukemia, myeloid, accelerated phase
blast crisis
leukemia, myeloid, chronic-phase
leukemia, lymphocytic, acute, L2
protein kinase inhibitors
orphan drug production
insurance, health, reimbursement
guidelines for drug use
protein-tyrosine kinases
Tyrosine Kinase Inhibitors
precursor cell lymphoblastic Leukemia-Lymphoma
---
